Long-term follow-up of three randomized trials comparing idarubicin and daunorubicin as induction therapies for patients with untreated acute myeloid leukemia

Cancer

Volumn 80, Issue 11 SUPPL., 1997, Pages 2181-2185

  Berman, Ellin ^a   Wiernik, Peter ^b   Vogler, Ralph ^c,g   Vélez Gárcia, Enrique ^d   Bartolucci, Alfred ^e   Whaley, Fredrick S ^f  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f PFIZER INC   (United States)

^g AMERICAN CANCER SOCIETY   (United States)

Author keywords

Acute myeloid leukemia; Daunorubicin; Idarubicin

Indexed keywords

DAUNORUBICIN; IDARUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

EID: 0030665746     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19971201)80:11+<2181::aid-cncr3>3.0.co;2-l     Document Type: Review

References (11)

1. Speth PAJ, van de Loo P, Linssen PCM, et al. Plasma and human leukemic cell pharmacokinetics of oral and intravenous 4-demethoxydaunomycin. Clin Pharmacol Ther 1986;40:643-9.
2. Berman E, McBride M. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug resistant leukemia cells. Blood 1992;79:3267-72.
3. Ross DD, Doyle LA, Yang W-D, et al. Idarubicin is less susceptible to transport mediated multidrug resistance than its metabolite idarubicinol or daunorubicin. Biochem Pharmacol 1995;50:1673-83.
4. Daghestani AN, Arlin ZA, Leyland-Jones B, et al. Phase I and II clinical and pharmacologic study of 4-demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia. Cancer Res 1985;45:1408-12.
5. Tan CT, Hancock C, Steinherz P, et al. Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer. Cancer Res 1987;47:2290-5.
6. Carella A, Santini G, Martinengo M, et al. 4-Demethoxydaunorubicin (idarubicin) in refractory or relapsed acute leukemia. Cancer 1985;55:1472.
7. Berman E, Heller G, Santorsa J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991;77:1666-76.
8. Wiernik P, Banks PLC, Case DC, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously treated adult patients with acute myeloid leukemia. Blood 1992;79:313-38.
9. Vogler R, Vélez-Gárcia E, Weiner R, et al. A phase II trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a South-eastern Cancer Study Group study. J Clin Oncol 1992; 10:1103-8.
10. Clarkson BD, Berman E, Little C, et al. Update on clinical trials of chemotherapy and bone marrow transplantation in acute myelogenous leukemia in adults at Memorial SloanKettering Cancer Center 1966-1989. In: Gale RP, editor. Acute myelogenous leukemia: progress and controversies. New York: Wiley-Liss; 1990:239-72.
11. Wheatley K, on behalf of the AML Collaborative Group. Meta-analysis of randomized trials of idarubicin or mitoxantrone versus daunorubicin as induction therapy for acute myeloid leukemia. Blood 1995;86:435a.